Literature DB >> 8091481

Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation.

V König1, U Hopf, P Neuhaus, J Bauditz, C A Schmidt, G Blumhardt, W O Bechstein, R Neuhaus, H Lobeck.   

Abstract

The outcome after OLT was studied in 53 patients with chronic hepatitis B virus (HBV)* infection, 15 of whom had, in addition, evidence of hepatitis delta virus (HDV) superinfection. Nine of 53 patients received short-term immunoprophylaxis with anti-hepatitis B surface (HBs) hyperimmunoglobulin up to 1 week after OLT and 44 of 53 patients received long-term unlimited immunoprophylaxis. Eight of 9 (89%) patients with short-term immunoprophylaxis showed reactivation of replication with HBV DNA in serum > 10 pg/ml independently of the preoperative HBV DNA level and HBsAg reappeared in all cases. Four (44%) patients in this group lost their graft because of fulminant hepatitis or cirrhosis and required retransplantation, and 2 patients (22%) died after reinfection in the second graft. Nineteen of 44 (43%) patients with long-term immunoprophylaxis developed HBV values > 10 pg/ml after transplant and 12 of 44 (27%) became HBsAg+ again. Most of them had quantifiable HBV DNA levels before OLT. Retransplantation was required in 5 of 44 (11%) patients and 4 of them died after HBV recurrence. The frequency of HBV reactivation and the development of viral hepatitis after OLT were associated with the preoperative presence of HBV, as determined by the molecular hybridization assay. With nested polymerase chain reaction, all 53 patients were HBV-DNA+ in the serum before and after OLT. with just one exception, none of the patients with HDV superinfection died, in spite of increased HDV replication after OLT. The data indicate that long-term immunoprophylaxis with anti-HBs hyperimmunoglobulin after OLT improves the prognosis in HBV-infected patients. The preoperative detection of HBV DNA in serum by molecular hybridization assay is correlated with graft infection and represents a prognostic parameter. The presence of HDV may have a protective effect after OLT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8091481     DOI: 10.1097/00007890-199409150-00005

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.

Authors:  Li Jiang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  Hepatitis B virus infection and liver transplantation.

Authors:  N A Terrault; T L Wright
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

3.  Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.

Authors:  J I Tchervenkov; A J Tector; J S Barkun; A Sherker; C D Forbes; N Elias; M Cantarovich; P Cleland; P Metrakos; J L Meakins
Journal:  Ann Surg       Date:  1997-09       Impact factor: 12.969

4.  Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis.

Authors:  Rohit Loomba; Ayana K Rowley; Robert Wesley; Karen G Smith; T Jake Liang; Frank Pucino; Gyorgy Csako
Journal:  Clin Gastroenterol Hepatol       Date:  2008-05-05       Impact factor: 11.382

5.  Prophylaxis of hepatitis B infection in solid organ transplant recipients.

Authors:  Savio John; Karin L Andersson; Camille N Kotton; Martin Hertl; James F Markmann; A Benedict Cosimi; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

6.  Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.

Authors:  R G Sawyer; R W McGory; M J Gaffey; C C McCullough; B L Shephard; C W Houlgrave; T S Ryan; M Kuhns; A McNamara; S H Caldwell; A Abdulkareem; T L Pruett
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

Review 7.  Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues.

Authors:  Ian R Schreibman; Eugene R Schiff
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-04-06       Impact factor: 3.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.